南财智讯1月30日电，双鹭药业发布2025年度业绩预告，预计2025年全年归属于上市公司股东的净利润 为-20,000万元—-29,000万元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润 为-7,000万元—-4,000万元。报告期内，受行业政策调整、市场竞争等因素影响，公司部分产品单价较 上年有所下降，导致本年度公司相关产品的销售毛利下降约10%；报告期内，公司非经常性损益合计减 少净利润约2亿元，其中：确认的理财投资损失与交易性金融资产等产生的公允价值变动收益是主要影 响因素。 ...

Core Viewpoint - Fu'an Pharmaceutical (300194) is expected to report a significant decline in net profit for the year 2025, with projections indicating a drop of 64.26% to 74.99% compared to the previous year [1] Financial Performance - The company anticipates a net profit of between 70 million to 100 million yuan for 2025 [1] - The net profit, excluding non-recurring gains and losses, is projected to be between 52 million to 78 million yuan, reflecting a decrease of 69.83% to 79.88% year-on-year [1]

Core Viewpoint - Lingkang Pharmaceutical announced a change in the purpose of its repurchased shares, shifting from an employee stock ownership plan and equity incentive to cancellation and reduction of registered capital [1] Summary by Relevant Sections - **Company Announcement** - On January 30, 2026, Lingkang Pharmaceutical will hold its sixth meeting of the fifth board of directors to review the proposal regarding the change in the purpose of repurchased shares and the cancellation of shares [1] - **Share Repurchase Details** - The company has 8,915,893 shares in its repurchase account that are currently unused [1] - **Change in Usage of Shares** - The intended use of the repurchased shares has been altered from "50% for employee stock ownership plan and 50% for equity incentives" to "for cancellation and reduction of registered capital" [1]

Core Viewpoint - The company Guangshentang (300436) has announced a projected net loss for 2025, estimating a loss between 170 million to 240 million yuan, compared to a loss of 156 million yuan in the previous year [4] Financial Performance - The projected net profit for 2025 is expected to be a loss of 1.7 billion to 2.4 billion yuan, with a non-recurring net profit loss estimated at 1.78 billion to 2.48 billion yuan, compared to a loss of 2 billion yuan in the previous year [4] - The company's price-to-book ratio (LF) is approximately 41.43 times, and the price-to-sales ratio (TTM) is about 36.83 times [4] - Historical net profit and non-recurring profit figures show a consistent trend of losses over the years, with the projected figures for 2025 indicating a continuation of this trend [6][7] Research and Development - The company maintains a focus on innovative drug development, with significant investments in research and clinical trials, particularly for the hepatitis B treatment drug GST-HG141, which has completed enrollment of 526 participants in its Phase III clinical trial [5] - The company anticipates completing the enrollment by mid-February 2026, with a potential slight increase in the final number of participants [5] - The company has conducted impairment tests on intangible assets, inventory, and fixed assets, leading to a projected impact of approximately 7.5 million yuan from non-recurring gains and losses, a decrease of about 35.73 million yuan year-on-year, primarily due to a significant reduction in government subsidies [5]

Core Viewpoint - The company, Hepalink (09989), expects a significant decline in net profit attributable to shareholders for the year ending December 31, 2025, projecting between RMB 284 million and RMB 377 million, representing a year-on-year decrease of 41.71% to 56.09% [1] Group 1: Financial Performance - The company reported notable growth in the global heparin product market, with steady sales performance across regions and an increase in market share, particularly with a double-digit growth in enoxaparin sales [1] - The decline in net profit is primarily attributed to a high base from the previous year, which included a one-time investment gain exceeding RMB 350 million [1] - The company's net profit, excluding non-recurring items, showed growth compared to the previous year, driven by steady increases in main business revenue and profit [1] Group 2: Operational Efficiency - The company has been enhancing financial management and optimizing resource allocation to improve operational efficiency and drive continuous improvement in profitability [1] - Despite the anticipated impact from the joint venture's underperformance in R&D, the company still achieved steady growth in net profit after excluding non-recurring items, demonstrating resilience and sustained growth capability in its core business [1]

南财智讯1月30日电，天宇股份发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 1.20亿元—1.60亿元，同比预增114.53%—186.05%；预计2025年全年归属于上市公司股东的扣除非经常 性损益的净利润为1.12亿元—1.52亿元，同比预增66.03%—125.32%。报告期内，公司业绩实现显著增 长，主要驱动因素包括：公司积极把握市场机遇，持续拓宽客户渠道并加强精细化管理，企业核心竞争 力得到进一步加强；主营业务拓展方面，通过优化产品结构、完善市场布局及加强成本管控等措施，有 效提升了公司非沙坦类业务及制剂业务的营收规模和毛利增长；公司通过大幅缩减外汇衍生品交易规模 有效降低损失。报告期内公司预计非经常性损益影响归属于上市公司的净利润金额约800万元，主要系 政府补助。 ...

Core Viewpoint - Haizheng Materials (688203.SH) forecasts a significant decline in net profit for the year 2025, projecting a profit of 7.5 million to 9.5 million yuan, which represents a decrease of 26.0046 million to 28.0046 million yuan compared to the previous year, equating to a year-on-year decline of 73.24% to 78.88% [1] Group 1 - The company reports steady progress in production and operations, with an upward trend in the sales volume of its main products [1] - The company is actively expanding and deepening its domestic market presence, resulting in increased sales revenue [1] - Market competition has led to downward pressure on product sales prices, which has compressed the gross profit margin [1] Group 2 - There has been a year-on-year decrease in interest income and foreign exchange gains, contributing to an increase in financial expenses for the company [1] - The transition of construction projects from investment to fixed assets has resulted in increased depreciation and tax expenses, further compressing profits for the period [1]

Core Viewpoint - Haizheng Biomedical Materials (688203.SH) forecasts a significant decline in net profit for the year 2025, projecting a profit of 7.5 million to 9.5 million yuan, which represents a decrease of 26.0046 million to 28.0046 million yuan compared to the previous year, equating to a year-on-year decline of 73.24% to 78.88% [1] Group 1 - The company reports steady progress in production and operations, with an upward trend in the sales volume of its main products [1] - The company is actively expanding and deepening its domestic market presence, resulting in increased sales revenue [1] - Market competition has led to downward pressure on product sales prices, which has compressed the gross profit margin [1] Group 2 - There has been a year-on-year decrease in interest income and foreign exchange gains, contributing to an increase in financial expenses [1] - The transition of construction projects from fundraising investments to fixed assets has resulted in higher depreciation and tax expenses, further squeezing profits for the period [1]

Core Viewpoint - The company expects a significant decline in net profit for 2025, projecting a range of 27.2 million to 39.3 million yuan, representing a year-on-year decrease of 35% to 55% due to increased expenses in various areas [1] Financial Performance - The anticipated decline in net profit is attributed to increased sales expenses from intensified efforts in the formulation market [1] - Management expenses have risen due to payments related to restructuring and intermediary fees [1] - Research and development expenses have increased as the company continues to invest in new product development and improve its R&D management system [1] - Other income has decreased due to a reduction in government subsidies related to daily operations [1] - The company has conducted a comprehensive review of its receivables and other assets, leading to an increase in asset impairment losses as it prepares for potential write-downs [1]

Group 1 - The company Jin Cheng Pharmaceutical announced on January 30 that it has recognized an asset impairment provision totaling 55.6624 million yuan, which will be included in the company's 2025 financial results [1] - This impairment is expected to reduce the net profit attributable to shareholders of the listed company by approximately 49.6106 million yuan for the year 2025 [1] - The total equity attributable to shareholders of the listed company will also decrease by about 49.6106 million yuan [1] Group 2 - The nuclear power construction industry is experiencing a surge, with equipment manufacturers reportedly busy with orders scheduled until 2028 [1] - Employees are working in three shifts, and production lines are operating 24 hours a day to meet the high demand [1]